Changhoon Ji

Company: AUTOTAC Bio

Job title: CTO & Executive Director

Seminars:

Harnessing the AUTOTAC Platform for Development of a First-In-Class Tau Aggregate Degrader: Bridging the Gap Between Discovery, Preclinical Candidacy & Clinical Trials 9:00 am

Development of a novel targeted protein degradation platform (AUTOTAC) via p62-dependent selective macro-autophagy Application of the AUTOTAC platform to develop a first-in-class tau aggregate degrader ready for clinical trials Translation of academic discovery into industry-level drug developmentRead more

day: Conference Day One

Panel Discussion – What Do We Need To Do To Get Protein Degraders To Clinic For Treating Neurodegenerative Disease? 10:00 am

How translatable are the current models to clinic and what do we need to advance them for approved use? What are the regulatory hurdles for protein degraders in neurodegenerative disease? What lessons have been learnt by past failures in neurodegenerative drug development that can inform the success of protein degraders? Read more

day: Conference Day One